Bykov K, et al. - The incidence of thromboembolic adverse events (TAEs) was assessed in haemophilia patients following exposure to bypassing agents. Across agents, no difference was apparent in the rate of TAEs but the data were compatible with a possibly increased rate associated with a combination therapy. This pointed towards the requirement for continuing safety monitoring via prospective registries or observational data.